

Pacritinib in Vacuoles, E1 Ubiquitin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

NCT06538181

Status	RECRUITING
Phase	Phase 1
Sponsor	Washington University School of Medicine
Enrollment	15 participants

Key Eligibility Criteria

Inclusion (30)

- Patients must have UBA1 mutation with a variant allele frequency (VAF) of e 2% detected on a next generation sequencing panel and have at least one of the following current or past clinical manifestation of VEXAS syndrome, as determined by the attending physician:
 - skin rash
 - vasculitis
 - chondritis
 - ocular/orbital inflammation (e.g., uveitis/iritis, episcleritis)
- ... and 25 more (see full listing online)

Exclusion (15)

- Prior use of pacritinib.
 - Use of another JAK inhibitor within 28 days of C1D1 of pacritinib.
 - Currently receiving any other investigational agents. Patients may be eligible after 28 day washout.
 - Thrombotic events (arterial or venous) within 60 days prior to enrollment.
 - Any recent clinically significant bleeding within at least 7 days prior to enrollment.
- ... and 10 more (see full listing online)

Locations (1 total)

Washington University School of Medicine, St Louis, Missouri, United States

<https://clinicaltrials.gov/study/NCT06538181>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).